The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1699-1705

  Al Batran, S E ^a   Pauligk, C ^a   Wirtz, R ^b   Werner, D ^a   Steinmetz, K ^a   Homann, N ^c   Schmalenberg, H ^d   Hofheinz, R D ^e   Hartmann, J T ^f   Atmaca, A ^a   Altmannsberger, H M ^a   Jager E ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b STRATIFYER Molecular Pathology GmbH   (Germany)

^c Kopf Hals und Plastische G   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF KIEL   (Germany)

Author keywords

Esophagogastric cancer; Gastric cancer; Gastroesophageal cancer; Matrix metalloproteinase 9; RNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR A;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GELATINASE B GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MARKER GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STOMACH CANCER; SURVIVAL TIME; VALIDATION STUDY; VASCULOTROPIN RECEPTOR A GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864304530     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr552     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]2010Lyon, FranceInternational Agency for Research on Cancerhttp://globocan.iarc.fr (7 July 2011, date last accessed)
2. Ajani JA, Barthel JS, Bekaii-Saab T et al. Gastric Cancer. J Natl Compr Canc Netw 2010; 8: 378-409.
3. Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer 2010; 11611: 2511-2518.
4. Patel PR, Yao JC, Hess K et al. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer 2007; 11010: 2186-2190.
5. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 3769742: 687-697.
6. Sengupta N, MacDonald TT. The role of matrix metalloproteinases in stromal/ epithelial interactions in the gut. Physiology 2007; 226: 401-409.
7. Liu A, Garg P, Yang S et al. Epidermal growth factor-like repeats of thrombospondins activate phospholipase Cγ and increase epithelial cell migration through indirect epidermal growth factor receptor activation. J Biol Chem 2009; 28410: 6389-6402.
8. Hiratsuka S, Nakamura K, Iwai S et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002; 24: 289-300.
9. Van Kempen LC, Rhee JS, Dehne K et al. Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation 2002; 709: 10610-623.
10. Hawinkels LJ, Zuidwijk K, Verspaget HW et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 2008; 4413: 1904-1913.
11. Ueno Y, Sakurai H, Tsunoda S et al. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer 2008; 1232: 340-347.
12. Muramatsu M, Yamamoto S, Osawa T et al. Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. Cancer Res 2010; 7020: 8211-8221.
13. Van Kempen LC, Coussens LM. MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2002; 24: 251-252.
14. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008; 133: 193-205.
15. Al-Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442.
16. Al-Batran SE, Hartmann JT, Hofheinz R et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008; 1911: 1882-1887.
17. Al-Batran S, Homann N, Hartmann JT et al. 5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2002; 28Suppl: 401315s
18. Bohmann K, Hennig G, Rogel U et al. RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 2009; 559: 1719-1727.
19. Turpeenniemi-Hujanen T Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005; 87: 287-297.
20. Sier CF, Kubben FJ, Ganesh S et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74: 413-417.
21. Kubben FJ, Sier CF, Van Duijn W et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 2006; 947: 1035-1040.
22. Chu D, Zhang Z, Li Y et al. Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer2010 December 8 [epub ahead of print], doi:10.1002/ ijc.25734
23. Mrena J, Wiksten JP, Nordling S et al. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol 2006; 596: 618-623.
24. Zhang S, Li L, Lin JY et al. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiness and metastasis of human gastric carcinoma. World J Gastroenterol 2003; 9: 899-904.
25. De Mingo M, Morán A, Sánchez-Pernaute A et al. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology 2007; 5473315-319.
26. Muroski ME, Roycik MD, Newcomer RG et al. Matrix metalloproteinase-9/ gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol 2008; 9134-46.
27. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006; 3183: 933-938.
28. Glimelius B, Ekström K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 82: 163-168.
29. Bramhall SR, Hallissey MT, Whiting J et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002; 8612: 1864-1870.
30. Chu QS, Forouzesh B, Syed S et al. A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 2007; 254: 359-367.